Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
An erratum to this article was published (Cardiovasc Diabetol, 18 Mar 2024 ↗)
Authors' conclusion
The cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD.
Study context
- Population
- Patients ≥18 years with T2D initiating empagliflozin or GLP-1 RA, 2014–2019, US Medicare and commercial claims141,541 matched pairs
- Participants
- 141,541 vs 141,541
- Exposure
- Empagliflozin vs GLP-1 RA
- Empagliflozinn = 141,541
- GLP-1RAn = 141,541reference
- Outcome
- Cardiorenal outcomes (overall)
Methodological details1:1 propensity score matched, US Medicare and commercial claims databases
- 1:1 propensity score matched
- US Medicare and commercial claims databases
Main finding
As reported in the abstract
Empagliflozin vs GLP-1RAHazard ratio (CI)
MI or stroke; RD −0.23 (−1.25, 0.79) per 1,000 person-years
0.99(0.92–1.07)
HHF; RD −2.28 (−2.98, −1.59) per 1,000 person-years
0.50(0.44–0.56)
MACE; RD −2.54 (−4.76, −0.32) per 1,000 person-years
0.90(0.82–0.99)
CV mortality or HHF; RD −4.11 (−5.95, −2.29) per 1,000 person-years
0.77(0.69–0.86)
ESKD (CKD stages 3-4); RD −6.77 (−11.97, −1.61) per 1,000 person-years
0.75(0.60–0.94)
Observational data: associations, not effects.
Further findings
Subgroups: age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), heart failure (HF)
- Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF
- Absolute risk reductions did not differ by sex
Original publication
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. Published 8 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →